I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.
Pioglitazone hydrochloride exhibits antiinflammatory and antiarteriosclerotic effects. It is used to prevent L-NAME-induced coronary inflammation and arteriosclerosis and to suppress increased TNF-α mRNA produced by aspirin-induced gastric mucosal injury. Pioglitazone Hydrochloride is an activator of PPAR γ. It is a PPARγ agonist and thiazolidinedione (TZD) anti-diabetic. Pioglitazone is a selective agonist of the nuclear receptor peroxisome proliferator-activated receptor γ (PPAR-γ) and to a lesser extent PPAR-α.
S Kersten; B Desvergne; W Wahli. Roles of PPARs in health and disease. Nature.2000, 405 (6785), 421-424.
Klemens Budde; Hans-Hellmut Neumayer; Lutz Fritsche; Wladyslaw Sulowicz; Tomasz Stompôr; David Eckland. The pharmacokinetics of pioglitazone in patients with impaired renal function. British Journal of Clinical Pharmacology.2003, 55 (4), 368-374.
Hazard Statements: H319
Causes serious eye irritation.
Precautionary Statements: P280i-P264-P305+P351+P338-P337+P313
Wear eye/face protection. Wash thoroughly after handling. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention.